CSE PREV
LAST 0.73
CHANGE 0.03
OTC PRVCF
FSE 18H
CSE: PREV
LAST: 0.73
CHANGE: 0.03
OTC: PRVCF
FSE: 18H
Download as PDF  

Secret Knock

VANCOUVER, British Columbia, June 16, 2016 - PreveCeutical Medical Inc. ("PreveCeutical", or the "Company"), a health and wellness company focused on utilizing nature and science for the benefit of health conscious consumers, is pleased to announce that it will be attending the upcoming Secret Knock event on July 10 – 13th in San Diego California.

Forbes.com ranks Secret Knock as the second best gathering for entrepreneurs worldwide, bringing together the most amazing people and successful entrepreneurs – present and future. The entire concept is that instead of hearing from only coaches, teachers and mentors, entrepreneurs and leaders learn real life success strategies from the people who have actually accomplished their goals and dreams.

“We are thrilled to include the PreveCeutical team at such an important time in the Company’s development,” said Greg Reid, Co-Founder of Secret Knock. “And we believe the team will dramatically accelerate their growth and sector leadership through the skills and relationships they develop with Secret Knock.”

Appointment of Brian Harris as Director

PreveCeutical is also pleased to announce the appointment of Brian Harris as Director. Brian currently serves as Vice President Corporate Development for the Company, and is Managing Partner at MSI Marketing Services International providing inspiration, capital and professional services for industry specific startups and early stage enterprises.

Prior to PreveCeutical, Brian served as a Director and CEO of Russell Breweries Inc., a TSX-V listed company; and prior to Russell served as a Director and SVP for EFTech Ltd., a public company listed on the ASX and a leading supplier of Electronic Funds Transfer services at the Point of Sale in Australia. “Brian has played a leading role in the development of PreveCeutical to date. He is a widely respected leader in the brand development and natural health sector, and we are delighted to recognize his contributions with this appointment,” said Stephen Van Deventer, Chairman and CEO at PreveCeutical. “We are grateful to Brian for his previous efforts, and look forward to working closely with him in his role as Director to shape the future of health and wellness with preventative medicine.”

About Preveceutical

For more information about PreveCeutical, please visit www.preveceutical.com, follow us on Twitter: https://twitter.com/preveceuticals, or on Facebook: www.facebook.com/Preveceutical

On Behalf of the Board,

"Stephen Van Deventer"
President and CEO

This news release may contain forward-looking statements, including without limitation, future operations of PreveCeutical Medical Inc. (the "Company"). Forward-looking statements address future events and conditions and therefore involve inherent risks, uncertainties and assumptions. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding-looking wording such as “may”, “expect”, “estimate”, “will”, “anticipate”, “intend”, “believe” and “continue” or the negative thereof or similar variations. Actual results may differ materially from those currently anticipated in such statements and the Company undertakes no obligation to update such statements, except as required by law. While such estimates and assumptions are considered reasonable by the management of the Company, they are inherently subject to significant business, economic, competitive and regulatory uncertainties and risks. In particular, there is no guarantee that the Blue Scorpion Venom will effectively treat or cure cancer or other diseases. Accordingly actual results may differ materially from those currently anticipated in such statements. The Company has made numerous assumptions regarding, among other things: the effectiveness of its products; the demand for its products and the stability of economic and market conditions. Investors are cautioned that all forward-looking statements involve risks and uncertainties, including: that the Company may lose or abandon or may fail to receive necessary licenses and permits; labour disputes; the Company may not receive the necessary regulatory approvals for its products; the increase in cost estimates and the potential for unexpected costs and expenses; general economic and market conditions may worsen; market shifts may require a change in strategic focus; the Company may not be able to raise additional funds when necessary; litigation; and competition. Factors that could cause actual results to differ materially from those in forward looking statements include continued availability of capital and financing and general economic, market or business conditions, consumer sentiment towards the Company’s products, competition, the failure of counterparties to perform their contractual obligations, and fees charged by service providers. All forward-looking statements concerning the Company's future plans and operations, including management's assessment of the Company's operational expectations or beliefs may be subject to certain assumptions, risks and uncertainties beyond the Company's control. Investors are cautioned that any such statements are not guarantees of future performance and that actual performance and financial results may differ materially from any estimates or projections. Accordingly, readers should not place undue reliance on forward-looking statements and information, which are qualified in their entirety by this cautionary statement. There can be no assurance that forward-looking information, or the material factors or assumptions used to develop such forward looking information, will prove to be accurate.

PreveCeutical Medical Inc. Suite 605 – 815 Hornby Street,
Vancouver, B.C., V6Z 2E6, Canada www.preveceutical.com
1 (866) 398-1288

Sign up for the latest news and updates